Research progress onneoadjuvant therapy in stage ⅢA-N2 non-small cell lung cancer / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
;
(6): 61-64, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-798809
ABSTRACT
ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Radiation Oncology
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS